An observational study in Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic and Leukemia, Myeloid, Acute, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.
This study will have participants both enrolled retrospectively and prospectively for azacitidine (AZA) treatment.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 290 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will consist of participants enrolled retrospectively, who initiate azacitidine (AZA) before enrollment and participants enrolled prospectively, who initiate AZA initiation at enrollment.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Participants who initiate Azacitidine (AZA) before enrollment
Participants who initiate AZA initiation at enrollment
Incidence of Adverse Events (AEs)
Time frame: Up to 12 Months
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 12 Months
Incidence of Adverse Drug Reactions (ADRs)
Time frame: Up to 12 Months
Best Overall response rate (ORR) defined as the proportion of participants who achieved best response of superior to stable disease
Time frame: Up to 12 Months
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb